TriangleNCT01724177 · OUTCOME
Kaplan-Meier Estimate for Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks
What was measured
Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive.
Analysis population: The EE population consisted of all participants who met basic protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of lenalidomide.
Groups in this outcome
Lenalidomide
Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity
| Group | Source count |
|---|---|
| Lenalidomide | 26 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lenalidomide | 88.10 | Not reported | 43.000 | 109.100 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 43.000
- upper Limit
- 109.100
- value
- 88.10
- denoms
- counts
- group Id
- OG000
- value
- 26
- units
- Participants
- description
- Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity
- id
- OG000
- title
- Lenalidomide
- param Type
- MEDIAN
- population Description
- The EE population consisted of all participants who met basic protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of lenalidomide.
- reporting Status
- POSTED
- time Frame
- From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks
- title
- Kaplan-Meier Estimate for Overall Survival
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice